<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372942</url>
  </required_header>
  <id_info>
    <org_study_id>University of Padua</org_study_id>
    <nct_id>NCT02372942</nct_id>
  </id_info>
  <brief_title>Lactoferrin or Progesterone for Prevention of Preterm Delivery</brief_title>
  <official_title>Lactoferrin or Progesterone for Prevention of Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary endpoint will be evaluate the effectiveness of vaginal lactoferrin in the reduction&#xD;
      of the 30% of preterm deliveries versus the use of progesterone, in specific selected&#xD;
      patients, with consequent improvement in neonatal outcome.&#xD;
&#xD;
      Secondary endpoint will be compare antibacterial and anti-inflammatory activity of&#xD;
      lactoferrin by evaluation of systemic biochemical and urinary markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM OF THE STUDY Primary endpoint will be evaluate the effectiveness of vaginal lactoferrin&#xD;
      in the reduction of the 30% of preterm deliveries versus the use of progesterone, in specific&#xD;
      selected patients, with consequent improvement in neonatal outcome.&#xD;
&#xD;
      Secondary endpoint will be compare antibacterial and anti-inflammatory activity of&#xD;
      lactoferrin by evaluation of systemic biochemical and urinary markers.&#xD;
&#xD;
      MATHERIAL AND METHODS Type of study: This is a randomized and open-label study (lactoferrin&#xD;
      vs progesterone), multicenter.&#xD;
&#xD;
      Population of study: pregnant women 18-43 years aged with singleton pregnancy, between 24 and&#xD;
      34 weeks' gestation, who were at risk of preterm delivery.&#xD;
&#xD;
      Investigational products:&#xD;
&#xD;
        -  Lactoferrin (Difesan, vaginal tablets 300 mg); it is used in acute vaginosis (300 mg&#xD;
           intravaginally once a day for seven consecutives days). Since there are no side effects,&#xD;
           for experimental purpose it will be used until 34 weeks of gestation.&#xD;
&#xD;
        -  Progesterone (Progeffik, vaginal suppositories 200 mg); in case of risk of premature&#xD;
           delivery the treatment consist in 200 mg intravaginally once a day, for a maximum of 10&#xD;
           weeks. In this protocol it will be used until 34 weeks of gestation.&#xD;
&#xD;
      Duration of study: considering the prevalence of the disease and the number of deliveries for&#xD;
      years, it will be concluded in 2015.&#xD;
&#xD;
      Centers: Department of Women's and Child's Health, Obstetrics and Gynecology Clinic,&#xD;
      University of Padua, Italy.&#xD;
&#xD;
      Others: Udine, Italy &quot;S. Maria della Misericordia Hospital&quot; Vicenza, Italy &quot;S. Bortolo&#xD;
      Hospital&quot; Ferrara, Italy Bologna, Italy Treviso, Italy&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  cervical length less than 25 mm between 24 and 34 weeks' gestation (with or without&#xD;
           funnelling)&#xD;
&#xD;
        -  cervical effacement less than 50 percent and cervical dilatation less than 3 cm&#xD;
&#xD;
        -  uterine contractions less than 4 in 30 minutes&#xD;
&#xD;
        -  singleton pregnancy&#xD;
&#xD;
        -  absence of chorioamnionitis signs (white cells count&lt; 15.000, Reactive Protein C&lt; 10&#xD;
           mg/l, Procalcitonin levels &lt; 0,05 ng/ml),&#xD;
&#xD;
        -  absence of premature membrane rupture (pPROM).&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Fetal abnormalities such as severe intrauterine growth restriction and fetal&#xD;
           malformations with progressive deterioration&#xD;
&#xD;
        2. Maternal diseases such as gestation diabetes insulin-treated, severe nephropaties,&#xD;
           severe cardiopathies, autoimmune diseases&#xD;
&#xD;
        3. Twin pregnancy&#xD;
&#xD;
        4. Signs of maternal infections (chorioamnionitis)&#xD;
&#xD;
        5. Premature rupture of membrane&#xD;
&#xD;
      Previous progesterone therapy during first trimester is not a contraindication for the&#xD;
      inclusion of the patients (interval at least 8-10 weeks of gestation).&#xD;
&#xD;
      Previous preterm birth is not a exclusion criteria for the randomization.&#xD;
&#xD;
      Evaluation scheme:&#xD;
&#xD;
        1. Verification of maternal compatibility with study criteria.&#xD;
&#xD;
        2. Accurate personal, familiar and obstetrical anamnesis.&#xD;
&#xD;
        3. Management of the patient according to the clinical protocol in case of risk of&#xD;
           premature delivery (induction of fetal lung maturity and tocolitic therapy)&#xD;
&#xD;
        4. Informed consent.&#xD;
&#xD;
        5. Patient randomization.&#xD;
&#xD;
        6. Obstetrical and ultrasound evaluation of pregnancy (cervical length, fetal growth and&#xD;
           fetal well-being at 7, 15 and 30 days from the randomized).&#xD;
&#xD;
        7. Monitoring of inflammatory markers (white blood cells, reactive protein C and&#xD;
           procalcitonin) at diagnosis, at 7 and 15 days from the recovery.&#xD;
&#xD;
        8. Execution of vaginal swab and urine culture at diagnosis and at 30 days from the&#xD;
           recovery.&#xD;
&#xD;
        9. Registration of pregnancy data, delivery and neonatal out come.&#xD;
&#xD;
      EXCLUSION CRITERIA&#xD;
&#xD;
      The patient will be excluded from the study if they do occur the following conditions during&#xD;
      administration of lactoferrin or progesterone:&#xD;
&#xD;
        1. Presence of regular, painful and frequent uterine contractions and progressive change in&#xD;
           the cervix (cervical effacement of 80 percent or greater and cervical dilatation greater&#xD;
           than 3 cm)&#xD;
&#xD;
        2. Modification of the inflammatory markers that are associated to changes to the&#xD;
           obstetrical visit or cervical length.&#xD;
&#xD;
      There are no costs because the check-up expected for the patient belong to clinic routine.&#xD;
&#xD;
      The patients will not pay the treatment because it will be provided by the Principal&#xD;
      Investigator.&#xD;
&#xD;
      MEASUREMENT&#xD;
&#xD;
        1. Obstetrical data: during recovery and till delivery (course of pregnancy, sonography&#xD;
           examination, biochemical tests, complications.&#xD;
&#xD;
        2. Perinatal data: gestational age at the time of delivery, way of delivery, sex, weight,&#xD;
           Apgar score, arterial and venous ph, base excess, p02, days of recovery in neonatal&#xD;
           intensive care unit, mechanical ventilation, neonatal morbidity, breastfeeding.&#xD;
&#xD;
        3. Epidemiological data: maternal and paternal data (age, BMI, smoke and socio-economical&#xD;
           status, parity, ethnic group, personal history). Familiar history.&#xD;
&#xD;
      SAMPLE SIZE The patients enrolled in the study are those treated for high risk of preterm&#xD;
      delivery that respected inclusion criteria. They are randomized in two groups, one group is&#xD;
      submitted to lactofferin, the other group receives progesterone. For the calculation of&#xD;
      sample size we considered a recent review that concluded that progesterone treatment&#xD;
      decreased the median risk of preterm birth by 22% (Likis F et al. Progestogens for preterm&#xD;
      birth prevention. Obstet Gynecol October 2012).&#xD;
&#xD;
      The primary outcome is to show that lactoferrin decreases the median risk of preterm birth by&#xD;
      30% ; We considered alfa 5% and predictive value of 80%; considering 10% of drop out we will&#xD;
      randomize 1030 women.&#xD;
&#xD;
      [n=p1(p1-100)+p2(p2-100)/(p1-p2)2 x 7.9]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delayed days of birth using lattoferrin or progesterone</measure>
    <time_frame>days or weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>neonatal outcome</measure>
    <time_frame>28 days and 2 years follou-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1030</enrollment>
  <condition>Preterm Delivery</condition>
  <arm_group>
    <arm_group_label>Lattoferrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Lattoferin for prevention of preterm delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Progesterone for prevention of preterm delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lattoferrin</intervention_name>
    <description>515 pregnant women using lattoferrin to prevent preterm delivery</description>
    <arm_group_label>Lattoferrin</arm_group_label>
    <other_name>Difesan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Progeffik</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cervical length less than 25 mm between 24 and 34 weeks' gestation (with or without&#xD;
             funnelling)&#xD;
&#xD;
               -  cervical effacement less than 50 percent and cervical dilatation less than 3 cm&#xD;
&#xD;
               -  uterine contractions less than 4 in 30 minutes&#xD;
&#xD;
               -  singleton pregnancy&#xD;
&#xD;
               -  absence of chorioamnionitis signs (white cells count&lt; 15.000, Reactive Protein C&lt;&#xD;
                  10 mg/l, Procalcitonin levels &lt; 0,05 ng/ml),&#xD;
&#xD;
               -  absence of premature membrane rupture (pPROM).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fetal abnormalities such as severe intrauterine growth restriction and fetal&#xD;
             malformations with progressive deterioration&#xD;
&#xD;
          -  Maternal diseases such as gestation diabetes insulin-treated, severe nephropaties,&#xD;
             severe cardiopathies, autoimmune diseases&#xD;
&#xD;
          -  Twin pregnancy&#xD;
&#xD;
          -  Signs of maternal infections (chorioamnionitis)&#xD;
&#xD;
          -  Premature rupture of membrane&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erich Cosmi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Erich Cosmi MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor in Obstetrica and Gynecolgy</investigator_title>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

